St. Jude Care & Treatment

Menu

Close

Recruiting

PARPAML: Talazoparib and Chemotherapy for Acute Myeloid Leukemia

About this study

Talazoparib is a medicine approved by the United States Food and Drug Administration (FDA) for the treatment of breast cancer.

In this study, we will use talazoparib and chemotherapy to treat acute myeloid leukemia (AML) or acute myeloid leukemia of ambiguous lineage (ALAL) that has returned (relapsed) or did not respond to treatment (refractory). We will test different doses of talazoparib along with 2 chemotherapy medicines (topotecan and gemcitabine) that are often used to treat cancers in children but which AML or ALAL are not treated with during initial treatment.

This is the first time this combination of medicines is used to treat these cancers. We want to study the effects of this treatment and the best doses of medicines to use in children and young adults.

Eligibility overview

  • Up to age 21
  • Relapsed or refractory acute myeloid leukemia or acute leukemia of ambiguous lineage

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

PARPAML: A Phase 1 Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy

Study goal:

To study the effects of talazoparib and chemotherapy for treating relapsed or refractory acute myeloid leukemia and acute myeloid leukemia of ambiguous lineage and to find the best dose for children and young adults.

Diagnosis:

Acute myeloid leukemia, acute leukemia of ambiguous lineage

Age:

Up to age 21

Clinical trials categories:

Childhood Cancer Leukemia Acute Myeloid Leukemia (AML)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more